Prnewswireยท2025-07-01 12:45Core Viewpoint - BioMarin Pharmaceutical Inc. has successfully completed the acquisition of Inozyme Pharma, Inc. for $4.00 per share in an all-cash transaction valued at approximately $270 million, enhancing BioMarin's enzyme therapies portfolio with the addition of late-stage therapy INZ-701 for ENPP1 Deficiency [1][2][3] Group 1: Acquisition Details - The acquisition agreement was initially announced on May 16, 2025, with a tender offer commencing on June 2, 2025, to acquire all outstanding shares of Inozyme at $4.00 per share [2] - The tender offer expired on June 30, 2025, with 45,455,118 shares validly tendered, representing about 70% of the total shares [3] - Following the merger, all remaining shares not tendered were converted into the right to receive $4.00 per share in cash, and the shares ceased trading on the Nasdaq Global Select Market [3] Group 2: Company Profiles - BioMarin is a global biotechnology company focused on developing medicines from genetic discoveries, with a strong pipeline and eight commercial therapies [5] - Inozyme Pharma is a clinical-stage biopharmaceutical company with a focus on therapeutics targeting the PPi-Adenosine Pathway, particularly for conditions like ENPP1 Deficiency [6]